遗传性血管性水肿治疗市场规模、份额、成长分析、按治疗方法、按给药途径、按分销管道、按最终用途、按地区 - 行业预测，2025-2032 年

2023 年全球遗传性血管性水肿药物市场规模价值27 亿美元，预计将从2024 年的27.7 亿美元增长到2032 年的33.7 亿美元，预测期内（2023-2032 年）的复合年增长率为1.1 %。

其在医疗保健领域的市场扩张很大程度上是由于人们越来越认识到治疗罕见疾病，特别是遗传性血管性水肿 (HAE) 的必要性。此疾病影响约五万人中的一人，全球盛行率为十五万人中的一人。血管性水肿的发生率不断上升，其特征是身体各部位突然肿胀，促使美国遗传性血管性水肿协会等组织加大宣传力度，倡导新的治疗方案和患者支持。最近的调查显示，医疗保健专业人员报告了治疗遗传性血管性水肿的进展，新的治疗方法改善了患者的治疗效果和满意度。在印度，估计有 30,000-50,000 人患有遗传性血管性水肿，主要由皮肤科医生、胃肠病学家和临床过敏专家治疗。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步

遗传性血管性水肿药物市场规模（依治疗）

• 市场概况
• C1 酯酶抑制剂
• 缓激肽B2受体拮抗剂
• 激肽释放酶抑制剂
• 其他的

遗传性血管性水肿药物市场规模（依给药途径）

• 市场概况
• 静脉
• 皮下
• 口服

遗传性血管性水肿药物市场规模（依分销管道）

• 市场概况
• 医院药房
• 零售药局
• 其他的

遗传性血管性水肿药物市场规模（依最终用途）

• 市场概况
• 预防
• 一经请求

遗传性血管性水肿治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• CSL Behring（Australia）
• Takeda Pharmaceutical Company Limited（Japan）
• Pharming Group NV（Netherlands）
• BioCryst Pharmaceuticals, Inc.（USA）
• Ionis Pharmaceuticals, Inc.（USA）
• Sanofi SA（France）
• Adverum Biotechnologies, Inc.（USA）
• KalVista Pharmaceuticals, Inc.（USA）
• Attune Pharmaceuticals, Inc.（USA）
• Arrowhead Pharmaceuticals, Inc.（USA）
• Amgen Inc.（USA）
• BioMarin Pharmaceutical Inc.（USA）
• Catalyst Biosciences, Inc.（USA）
• RUCONEST（Pharming Group NV, Netherlands）
• Haegarda（CSL Limited, Australia）
• Firazyr（Shire plc, UK）
• Dyax Corp.（USA）
• Adverum Biotechnologies, Inc.（USA）
• Amgen Inc.（USA）

结论和建议

Global Hereditary Angioedema Treatment Market size was valued at USD 2.7 billion in 2023 and is poised to grow from USD 2.77 billion in 2024 to USD 3.37 billion by 2032, growing at a CAGR of 2.5% during the forecast period (2025-2032).

Market expansion in the healthcare sector is significantly driven by the growing recognition of the need for treatments for rare disorders, notably hereditary angioedema (HAE). This condition affects approximately 1 in 50,000 individuals, with a global prevalence of 1 in 150,000. The increasing incidence of angioedema attacks, characterized by sudden swelling in various body regions, is leading to heightened awareness efforts by organizations like the US Hereditary Angioedema Association, which advocates for modern treatment options and support for patients. Recent surveys show that healthcare professionals have reported advancements in HAE management, with improved patient outcomes and satisfaction due to novel therapies. In India, an estimated 30,000-50,000 individuals suffer from HAE, predominantly treated by dermatologists, gastroenterologists, and clinical allergists.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hereditary Angioedema Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hereditary Angioedema Treatment Market Segmental Analysis

Global Hereditary Angioedema Treatment Market is segmented by Treatment, Route of Administration, Distribution Channel, End Use and region. Based on Treatment, the market is segmented into C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor and Others. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Others. Based on End Use, the market is segmented into Prophylaxis and On-demand. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hereditary Angioedema Treatment Market

The global hereditary angioedema treatment market is significantly driven by a heightened focus on advanced therapeutics aimed at managing these disorders. Researchers and manufacturers worldwide are diligently working to develop and enhance therapies for hereditary angioedema, as evidenced by numerous new medication applications for C1-esterase inhibitors, Bradykinin B2 receptor antagonists, and Kallikrein inhibitors targeting Types I, II, and III HAE. This surge in sophisticated treatment options, coupled with rising awareness and the increasing prevalence of rare diseases, has accelerated market growth. Recent approvals of innovative medications and a promising pipeline for future drug developments further bolster this expansion, alongside the growing impact of severe edema episodes linked to elevated estrogen levels and ACE inhibitor usage.

Restraints in the Global Hereditary Angioedema Treatment Market

The growth of the global hereditary angioedema treatment market is significantly hindered by the frequent misdiagnosis of the condition, often mistaken for common allergies, appendicitis, and irritable bowel syndrome. This misidentification stems from a widespread lack of awareness regarding hereditary angioedema (HAE), resulting in inadequate treatment for those affected. Consequently, many individuals suffering from HAE receive incorrect diagnoses, frequently being categorized under gastrointestinal disorders or non-allergic angioedema, thereby delaying appropriate care. This prevalent issue not only disrupts the treatment process for patients but also stifles advancements and expansion within the hereditary angioedema treatment market as a whole.

Market Trends of the Global Hereditary Angioedema Treatment Market

The Global Hereditary Angioedema (HAE) Treatment market is witnessing significant growth driven by increased awareness of rare conditions and the emergence of innovative therapies. Key catalysts include the introduction of novel therapeutics and pipeline medications, exemplified by recent products like Takhzyro (lanadelumab), which addresses prophylactic HAE treatment. A notable trend is the shift towards oral delivery methods, enhancing patient convenience and minimizing adverse effects compared to traditional treatments. As pharmaceutical companies explore the rare disease sector, the influx of new entrants with promising products suggests a competitive landscape poised for expansion. This dynamic environment is expected to further accelerate market growth and improve treatment accessibility for HAE patients globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Hereditary Angioedema Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• C1-esterase inhibitor
• Bradykinin B2 receptor antagonist
• Kallikrein inhibitor
• Others

Global Hereditary Angioedema Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Subcutaneous
• Oral

Global Hereditary Angioedema Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Hereditary Angioedema Treatment Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Prophylaxis
• On-demand

Global Hereditary Angioedema Treatment Market Size & CAGR (2025-2032)

• North America (Treatment, Route of Administration, Distribution Channel, End Use)
  • US
  • Canada
• Europe (Treatment, Route of Administration, Distribution Channel, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Route of Administration, Distribution Channel, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Route of Administration, Distribution Channel, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Route of Administration, Distribution Channel, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharming Group N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KalVista Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Attune Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arrowhead Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RUCONEST (Pharming Group N.V., Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haegarda (CSL Limited, Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Firazyr (Shire plc, UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dyax Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations